In a pathology lab, a cancer diagnosis begins not with an algorithm, but with a barcode. A glass slide is scanned, creating a massive digital image, and then it must be tracked, managed, and routed to the right expert. For Virasoft, an eight-year-old company operating between New York and Istanbul, this unglamorous workflow is the critical wedge. The company reports its software now handles 400,000 diagnostic cases annually across more than 20 institutions, a volume that underscores a quiet, operational bet in the crowded field of AI-powered cancer diagnostics [Virasoft website].
The workflow-first wedge
While competitors like PathAI and Paige often lead with flashy AI algorithms for detecting cancer cells, Virasoft's public positioning emphasizes the foundational plumbing. Its core product is APLIS, an Anatomic Pathology Laboratory Information System designed to manage lab operations via barcode tracking and sample logistics [Perplexity Sonar Pro]. This is paired with a CE-IVDR certified Image Management System, a regulatory milestone in Europe that allows the platform to be used for primary diagnosis using whole slide images [Perplexity Sonar Pro]. The company's AI-based decision support tools are presented as an integrated layer atop this certified workflow backbone. The strategy is pragmatic: sell the indispensable operating system first, then deepen the value with analytical tools.
Traction in a regulated landscape
The company's reported scale,400,000 cases annually,suggests a product that has found adoption, particularly in its home region. Pathology labs have been using Virasoft's digital pathology solutions since 2019, according to company materials [Perplexity Sonar Pro]. With an estimated 30 employees and revenue under $5 million, the operation remains capital-efficient, having raised only undisclosed seed rounds in 2017 and again in May 2025 [Perplexity Sonar Pro] [Crunchbase, May 2025]. The leadership team, co-founded by Gökhan Hatipoğlu and Samet Ayalti, has maintained a steady, if under-the-radar, build for nearly a decade.
Key Virasoft Metrics (Estimated)
| Metric | Figure | Source |
|---|---|---|
| Annual Case Volume | 400,000 | [Virasoft website] |
| Customer Institutions | 20+ | [Virasoft website] |
| Headcount | ~30 | [Perplexity Sonar Pro] |
| Revenue | <$5M | [Perplexity Sonar Pro] |
| Latest Funding | Seed (May 2025) | [Crunchbase, May 2025] |
The crowded field of digital pathology
Virasoft's path is not without formidable obstacles. It operates in a space defined by well-funded, research-heavy players. The competitive landscape presents a clear tiered structure:
- PathAI & Paige. The category leaders, with substantial venture backing and high-profile partnerships with pharmaceutical giants and academic medical centers. Their differentiation is deeply rooted in proprietary AI models and large-scale clinical validation studies.
- Proscia. A strong contender focusing on the digital pathology platform itself, competing directly on the workflow and image management layer that Virasoft emphasizes.
- Virasoft. Positions itself with a cost-effective, certified workflow system that has proven adoption, particularly in Turkey and surrounding regions. Its AI tools are part of the suite but not necessarily the primary lead.
The risk for Virasoft is that its workflow-centric approach could be commoditized or outspent by larger platforms as they expand their own operational features. Furthermore, the company's undisclosed funding and lack of named institutional investors in the public record raise questions about its war chest for the commercial battles ahead, especially in North America and Western Europe.
The patient at the end of the slide
For all the talk of workflows and certifications, the ultimate output is a diagnosis for a person waiting for answers. Virasoft's tools are designed for pathologists interpreting biopsies for cancers, a process where accuracy and speed directly impact treatment timelines. The standard of care in many regions still relies on a pathologist peering through a conventional microscope at a physical glass slide, a manual process prone to fatigue and subjectivity. Digital pathology, even without AI, represents a step forward by enabling remote consultation, easier archival, and now, with platforms like Virasoft's, structured tracking of the entire diagnostic journey. The company's bet is that by making this digital transition reliable and regulatorily sound, it creates the essential substrate upon which more advanced AI,theirs or others',can later be safely built.
Sources
- [Virasoft website] Virasoft - Digital Pathology Workflow & AI Solutions | https://www.virasoft.com/
- [Perplexity Sonar Pro] Virasoft: Research Brief | (Source from research snippets)
- [Crunchbase, May 2025] Venture Round - Virasoft - 2025-05-21 | https://www.crunchbase.com/funding_round/virasoft-series-unknown--ed8ea65c
- [Crunchbase, Aug 2017] Pre Seed Round - Virasoft - 2017-08-02 | https://www.crunchbase.com/funding_round/virasoft-pre-seed--e7288ef0